Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
Shanmugam Muthusamy, Head of R&D, COO-Novitium Ops at ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold a total of 100,000 shares of common stock in two separate transactions, realizing approximately $8.8 million.
On August 14, 2025, Muthusamy sold 47,010 shares at a weighted average price of $89.48, in a range of $88.20 to $90.11 per share. The total value of this transaction was approximately $4.2 million.
Following this, on August 15, 2025, Muthusamy sold an additional 52,990 shares at a weighted average price of $87.15, in a range of $85.44 to $90.00 per share. The total value of this transaction was approximately $4.6 million.
Following the transactions, Muthusamy directly owns 92,588 shares of ANI Pharmaceuticals Inc. common stock. Muthusamy also indirectly owns 531,920 shares through Esjay LLC and 5,000 shares through SS Pharma LLC.
In other recent news, ANI Pharmaceuticals reported impressive financial results for the second quarter of 2025. The company achieved adjusted earnings per share of $1.80, surpassing the FactSet consensus estimate of $1.41, which represents a notable 28.57% surprise. Revenue also exceeded expectations, reaching $211.4 million compared to the forecast of $187.34 million. The strong performance was driven in part by significant growth in the Cortrophin Gel product line, with revenue hitting $81.6 million, marking a 66% increase year-over-year. Following these results, ANI Pharmaceuticals raised its guidance for revenue, adjusted EBITDA, and EPS.
In response to these developments, H.C. Wainwright raised its price target for ANI Pharmaceuticals from $84 to $93, maintaining a Buy rating. Similarly, Truist Securities increased its price target from $65 to $77, while keeping a Hold rating. Both firms cited the company’s strong second-quarter performance as a key factor for their revised targets. These updates reflect the positive sentiment among analysts regarding ANI Pharmaceuticals’ recent achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.